Fricke J, Avila G, Keller T, Weller K, Lau S, Maurer M, et al. Prevalence of chronic urticaria in children and adults across the globe: systematic review with meta-analysis. Allergy. 2020;75:423–32.

Article  PubMed  Google Scholar 

Goncalo M, Gimenez-Arnau A, Al-Ahmad M, Ben-Shoshan M, Bernstein JA, Ensina LF, et al. The global burden of chronic urticaria for the patient and society. Br J Dermatol. 2021;184:226–36.

Article  CAS  PubMed  Google Scholar 

Konstantinou GN, Konstantinou GN. Psychiatric comorbidities in children and adolescents with chronic urticaria. World J Pediatr. 2023;19:315–22.

Article  PubMed  Google Scholar 

Zhao Z, Cai T, Chen H, Chen L, Chen Y, Gao X, et al. Expert consensus on the use of omalizumab in chronic urticaria in China. World Allergy Organ J. 2021;14:100610.

Article  PubMed  PubMed Central  Google Scholar 

Sarti L, Barni S, Giovannini M, Liccioli G, Novembre E, Mori F. Efficacy and tolerability of the updosing of second-generation non-sedating H1 antihistamines in children with chronic spontaneous urticaria. Pediatr Allergy Immunol. 2021;32:153–60.

Article  CAS  PubMed  Google Scholar 

Zuberbier T, Abdul Latiff AH, Abuzakouk M, Aquilina S, Asero R, Baker D, et al. The international EAACI/GA(2)LEN/EuroGuiDerm/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria. Allergy. 2022;77:734–66.

Article  PubMed  Google Scholar 

Gimenez-Arnau AM. Omalizumab for treating chronic spontaneous urticaria: an expert review on efficacy and safety. Expert Opin Biol Ther. 2017;17:375–85.

Article  CAS  PubMed  Google Scholar 

Maurer M, Rosén K, Hsieh HJ, Saini S, Grattan C, Gimenéz-Arnau A, Agarwal S, Doyle R, Canvin J, Kaplan A, Casale T. Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria. N Engl J Med. 2013;368:924–35.

Article  CAS  PubMed  Google Scholar 

Staubach P, Peveling-Oberhag A, Lang BM, Zimmer S, Sohn A, Mann C. Severe chronic spontaneous urticaria in children - treatment options according to the guidelines and beyond - a 10 years review. J Dermatolog Treat. 2022;33:1119–22.

Article  CAS  PubMed  Google Scholar 

Mitra D. A randomized, double-blind, placebo-controlled study of monoclonal anti-IgE antibody omalizumab in the management of pruritus in chronic spontaneous urticaria in the pediatric population. Pediatr Dermatol. 2018;35:712–3.

Google Scholar 

Wang A, Yun Y, Wen Z, Gao Y, Qi S, Zhang Y, et al. Efficacy and safety of omalizumab against chronic spontaneous urticaria: real-world study from China. World Allergy Organ J. 2022;15:100719.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Dekkers C, Alizadeh Aghdam M, de Graaf M, Knulst AC, Meijer Y, van den Reek J, et al. Safety and effectiveness of omalizumab for the treatment of chronic urticaria in pediatric patients. Pediatr Allergy Immunol. 2021;32:720–6.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Song XT, Chen YD, Yu M, Liu B, Zhao ZT, Maurer M. Omalizumab in children and adolescents with chronic urticaria: a 16 week real-world study. Allergy. 2021;76:1271–3.

Article  PubMed  Google Scholar 

Ari A, Levy Y, Segal N, Maoz-Segal R, Benor S, Broides A, et al. Efficacy of omalizumab treatment for pediatric chronic spontaneous urticaria: a multi-center retrospective case series. Pediatr Dermatol. 2020;37:1051–4.

Article  PubMed  Google Scholar 

Guarracino C, Tomasoni A, Marseglia A, Marseglia GL, Licari A. Real-life data on the effectiveness and safety of omalizumab in adolescents with chronic spontaneous urticaria: a retrospective study. Pediatr Allergy Immunol. 2020;31:79.

Google Scholar 

Kalugina V, Namazova-Baranova L, Vishneva E, Alekseeva A, Dobrynina E, Levina J, et al. Evaluating the efficacy of omalizumab therapy in a group of adolescents with chronic urticaria in real clinical practice. World Allergy Org J. 2020;13:100316.

Article  Google Scholar 

Gabrielli S, Netchiporouk E, Baum S, Greenberger S, Staubach-Renz P, Ben-Shoshan M. Management of Chronic Urticaria in a Pediatric Population. J Allergy Clin Immunol. 2019;143:AB301. 

Article  Google Scholar 

Kahveci M, Sahiner ÜM, Büyüktiryaki B, Sekerel BE, Soyer O. Omalizumab treatment in children with chronic spontaneous urticaria: efficacy and safety. Allergy Eur J Allergy Clin Immunol. 2019;74:867–8.

Google Scholar 

Cekic S, Karali Y, Canitez Y, Sapan N. Omalizumab treatment in childhood chronic urticaria. Allergy. 2018;73:227.

Google Scholar 

El Bilali J, Gabrielli S, Shand G, Netichoprouk E, Ben-Shoshan M. Omalizumab for management of chronic urticaria in a pediatric population: a case-series. J Allergy Clin Immunol. 2018;141:AB55.

Article  Google Scholar 

Staubach P, Peveling-Oberhag A, Jäger M, Lang B, Sohn A, Geppert C, et al. Antihistamine-resistant chronic spontaneous urticaria in children-treatment with omalizumab. Pediatr Dermatol. 2017;34:S50.

Google Scholar 

Vishneva E, Namazova-Baranova L, Alekseeva A, Levina J, Kalugina V, Efendieva K, et al. Successful omalizumab treatment in adolescents with chronic urticaria. Allergy. 2018;73:137.

Google Scholar 

Passanisi S, Arasi S, Caminiti L, Crisafulli G, Salzano G, Pajno GB. Omalizumab in children and adolescents with chronic spontaneous urticaria: case series and review of the literature. Dermatol Ther. 2020;33:e13489.

Article  CAS  PubMed  Google Scholar 

Al-Shaikhly T, Rosenthal JA, Ayars AG, Petroni DH. Omalizumab for chronic urticaria in children younger than 12 years. Annals Allergy Asthma Immunol. 2019;123:208–210e202.

Article  Google Scholar 

Petrovicová O, Jesenak M, Kapustova L, Banovcin P. Off-label use of omalizumab for chronic spontaneous urticaria in children younger than 12 years (experience of one centre). Allergy Eur J Allergy Clin Immunol. 2020;75:434–5.

Google Scholar 

Kalugina VG, Vishneva EA, Namazova-Baranova LS. Efficiency of adding omalizumab to standard therapy for children with recurrent spontaneous urticaria: Comparative observational study. Pediatricheskaya Farmakologiya. 2020;17:179–86.

Article  Google Scholar 

Agache I, Rocha C, Pereira A, Song Y, Alonso-Coello P, Sola I, et al. Efficacy and safety of treatment with omalizumab for chronic spontaneous urticaria: a systematic review for the EAACI Biologicals Guidelines. Allergy. 2021;76:59–70.

Article  CAS  PubMed  Google Scholar